HK1198333A1 - 抗纤维化肽及其在用於治疗以纤维化为特徵的疾病和病症的方法中的用途 - Google Patents

抗纤维化肽及其在用於治疗以纤维化为特徵的疾病和病症的方法中的用途 Download PDF

Info

Publication number
HK1198333A1
HK1198333A1 HK14111848.5A HK14111848A HK1198333A1 HK 1198333 A1 HK1198333 A1 HK 1198333A1 HK 14111848 A HK14111848 A HK 14111848A HK 1198333 A1 HK1198333 A1 HK 1198333A1
Authority
HK
Hong Kong
Prior art keywords
fibrosis
methods
treating diseases
disorders characterized
peptides
Prior art date
Application number
HK14111848.5A
Other languages
English (en)
Chinese (zh)
Inventor
Dattatreyamurty Bosukonda
Peter C. Keck
Original Assignee
Thrasos Innovation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrasos Innovation, Inc. filed Critical Thrasos Innovation, Inc.
Publication of HK1198333A1 publication Critical patent/HK1198333A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK14111848.5A 2011-07-19 2012-07-19 抗纤维化肽及其在用於治疗以纤维化为特徵的疾病和病症的方法中的用途 HK1198333A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161509340P 2011-07-19 2011-07-19
US61/509,340 2011-07-19
US201261662337P 2012-06-20 2012-06-20
US61/662,337 2012-06-20
PCT/US2012/047468 WO2013013085A2 (en) 2011-07-19 2012-07-19 Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis

Publications (1)

Publication Number Publication Date
HK1198333A1 true HK1198333A1 (zh) 2015-04-02

Family

ID=47558730

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14111848.5A HK1198333A1 (zh) 2011-07-19 2012-07-19 抗纤维化肽及其在用於治疗以纤维化为特徵的疾病和病症的方法中的用途

Country Status (11)

Country Link
US (2) US20140057831A1 (enExample)
EP (1) EP2734220A4 (enExample)
JP (1) JP2014527040A (enExample)
CN (2) CN106478776A (enExample)
AU (1) AU2012283924A1 (enExample)
BR (1) BR112014001268A2 (enExample)
CA (1) CA2842330A1 (enExample)
HK (1) HK1198333A1 (enExample)
IL (1) IL230510A0 (enExample)
RU (1) RU2014105513A (enExample)
WO (1) WO2013013085A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232276A1 (en) * 2014-09-30 2017-08-17 Primegen Biotech, Llc Treatment of fibrosis using deep tissue heating and stem cell therapy
US20160137714A1 (en) * 2014-11-12 2016-05-19 Thrasos Innovation, Inc. Peptides with enhanced stability and their use in methods for treating diseases
WO2016179106A1 (en) * 2015-05-01 2016-11-10 University Of Miami Methods and compositions for converting non-endocrine pancreatic tissue into insulin-producing cells
CN114181281A (zh) * 2015-05-12 2022-03-15 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗
US10844392B2 (en) * 2015-06-05 2020-11-24 Ibio, Inc. Materials and methods for producing endostatin fusion polypeptides in plant cells
WO2019133950A1 (en) * 2017-12-30 2019-07-04 The Regents Of The University Of Colorado, A Body Corporate Smad7 for treatment and prevention of posterior capsule opacification
ES2906715T3 (es) * 2018-09-06 2022-04-20 Marine Essence Biosciences Corp Of Usa Dispositivos de biomaterial para la regeneración de tejidos guiada
AU2019366366B2 (en) * 2018-10-22 2025-09-25 William D. Carlson Therapeutic combinations of TDFRPs and additional agents and methods of use
WO2021007094A1 (en) * 2019-07-10 2021-01-14 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
CN117106029A (zh) * 2020-06-08 2023-11-24 深圳市图微安创科技开发有限公司 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途
CA3212468A1 (en) * 2021-03-16 2022-09-22 William D. Carlson Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis
CN113069531B (zh) * 2021-04-09 2023-02-28 南开大学 一种防疤痕皮肤创伤修复用水凝胶及其制备方法
CN116768974A (zh) * 2022-03-11 2023-09-19 中山大学 用于预防和/或治疗肾纤维化的多肽化合物
EP4601667A1 (en) 2022-10-10 2025-08-20 Therapeutics by Design, LLC Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury
CN117653714A (zh) * 2023-03-22 2024-03-08 宁夏医科大学 AAV9-HGF联合TGF-β-Smad受体抑制剂SB431542在治疗矽肺纤维化中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE493141T1 (de) * 1996-03-22 2011-01-15 Stryker Corp Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
EP1572950B1 (en) * 2002-06-17 2012-10-10 Thrasos, Inc. Single domain tdf-related compounds and analogs thereof
EP2789342A1 (en) * 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
US8299212B2 (en) * 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
US20110275574A1 (en) * 2009-01-16 2011-11-10 Agency For Science, Technology And Research Method of inhibiting proliferation of hepatic stellate cells
US8642834B2 (en) * 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010128158A1 (en) * 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders

Also Published As

Publication number Publication date
WO2013013085A3 (en) 2014-03-13
JP2014527040A (ja) 2014-10-09
US20160058829A1 (en) 2016-03-03
AU2012283924A1 (en) 2014-02-06
EP2734220A4 (en) 2015-01-21
CN103890003A (zh) 2014-06-25
CN103890003B (zh) 2016-08-24
CA2842330A1 (en) 2013-01-24
CN106478776A (zh) 2017-03-08
US20140057831A1 (en) 2014-02-27
EP2734220A2 (en) 2014-05-28
IL230510A0 (en) 2014-03-31
WO2013013085A2 (en) 2013-01-24
RU2014105513A (ru) 2015-08-27
BR112014001268A2 (pt) 2017-02-21

Similar Documents

Publication Publication Date Title
WO2013013085A3 (en) Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
SG10201805670QA (en) Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2013012752A3 (en) Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
SG10201704696QA (en) Electrolyte formulations for use in biocompatible energization elements
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
WO2015026494A3 (en) Methods for treating tissue fibrosis
EP3090195A4 (en) Non return valve for use in water line
EP3263584A4 (en) Peptide for targeting autophagic cells and use thereof
MX374220B (es) Nepentesina para usarse en el tratamiento de la intolerancia al gluten y padecimientos relacionados.
WO2013029011A8 (en) Methods and compositions comprising a c-terminal bax peptide
GB2589744B (en) Geoengineering constructions for use in railways
SG11201504729VA (en) Ag-In ALLOY SPUTTERING TARGET
SG10201508365RA (en) Preventive or therapeutic agent for fibrosis
HK1215571A1 (zh) 二盐酸科比思特
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
PT2648666T (pt) Dispositivo de laser, especialmente para cirurgia oftalmológica a laser
IL264205A (en) Cellular compounds for tissue regeneration
PL2723385T3 (pl) Kompozycja błonotwórcza i jej zastosowanie do leczenia opryszczki
IL251698A0 (en) A modular structure to support objects, especially tableware
EP3279347A4 (en) Steel alloy for use in water supply member